Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
This Morning's Technical Outlook on Biotech Stocks -- NewLink Genetics, OHR Pharma, Omeros, and OncoSec Medical

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on NLNK, OHRP, OMER, and ONCS which can be accessed for free by signing up to www.wallstequities.com/registration....

OHRP : 0.25 (-3.85%)
ONCS : 1.77 (-2.75%)
OMER : 9.00 (-14.77%)
NLNK : 7.00 (-0.14%)
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative immunotherapies and proprietary medical approaches to stimulate...

ONCS : 1.77 (-2.75%)
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock

SAN DIEGO , Feb. 6, 2018 /PRNewswire/ --  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative immunotherapies...

ONCS : 1.77 (-2.75%)
OncoSec Medical Incorporated Prices $20.0 Million Public Offering of Common Stock

SAN DIEGO , Feb. 1, 2018 /PRNewswire/ --  OncoSec Medical Incorporated (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary...

ONCS : 1.77 (-2.75%)
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock

OncoSec Medical Incorporated (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide...

ONCS : 1.77 (-2.75%)
OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced preliminary clinical observations related to its pilot...

ONCS : 1.77 (-2.75%)
OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Gregory T. Mayes to its board of directors....

ONCS : 1.77 (-2.75%)
OncoSec Provides 2018 Business Outlook

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced its anticipated operational milestones for 2018 and a review...

ONCS : 1.77 (-2.75%)
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the initiation of patient dosing in PISCES/KEYNOTE-695,...

ONCS : 1.77 (-2.75%)
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

SAN DIEGO , Dec. 14, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the initiation...

ONCS : 1.77 (-2.75%)
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer....

ONCS : 1.77 (-2.75%)
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer

SAN DIEGO , Dec. 5, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher...

ONCS : 1.77 (-2.75%)
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has added two patents to its broad patent portfolio....

ONCS : 1.77 (-2.75%)
OncoSec Receives $9.3 Million Warrant Exercise

SAN DIEGO , Nov. 13, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has...

ONCS : 1.77 (-2.75%)
OncoSec Receives $9.3 Million Warrant Exercise

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into entered into a Warrant Exercise Agreement...

ONCS : 1.77 (-2.75%)
Corporate News Blog - OncoSec Medical Reports Positive Updated Follow-Up Data from Phase-2 Trial of ImmunoPulse IL-12 in Combination with Pembrolizumab

Research Desk Line-up: Radius Health Post Earnings Coverage

RDUS : 38.95 (+3.29%)
ONCS : 1.77 (-2.75%)
2 Stocks That Should Be on Your Radar Now

CORAL GABLES, FL / ACCESSWIRE / November 9, 2017 / Lexington Biosciences, Inc. (LXGTF) is a medical device company that is focusing on measuring and monitoring the cardiovascular system. The company's...

LXGTF : 0.3850 (+4.05%)
ONCS : 1.77 (-2.75%)
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based cancer immunotherapies, will present emerging data from its novel, multi-gene expression platform termed Polycistronic...

ONCS : 1.77 (-2.75%)
OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients

OncoSec Medical Incorporated ("OncoSec" or "Company") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced positive updated long-term follow-up data from its...

ONCS : 1.77 (-2.75%)
OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company

OncoSec Medical Incorporated ("OncoSec" or "Company") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O'Connor as CEO of...

ONCS : 1.77 (-2.75%)

Van Meerten Stock Picks

Nvidia - My Favorite S\&P 500 Large Cap Stock
$NVDA Summary96% technical by signals.
NVDA +0.64
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.32%) this morning are up +0.12% as they recovered from a 1-week low in overnight trade. Stocks rebounded on upbeat Fed commentary after Fed Governor Quarles said the U.S. economy is in the... Read More

Chart of the Day

Natural Alternativ (NAII)

Natural Alternatives International (NAII) is the Barchart Chart of the Day.  The natural supplement company has a Trend Spotter buy signal, a Weighted Alpga of 34.20+ and gained 32.42% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed the day with steady to penny gains on Wednesday. The USDA announced a private export sale of 130,000 MT of 17/18 corn to unknown destinations this morning. The weekly EIA report showed ethanol production picking up to 1.068 millio...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.